Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Omeros Corp
(NQ:
OMER
)
3.750
+0.070 (+1.90%)
Streaming Delayed Price
Updated: 1:12 PM EDT, Sep 12, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Omeros Corp
< Previous
1
2
3
Next >
Omeros Corporation Receives $200 Million Milestone Payment from Rayner Surgical
February 06, 2023
From
Omeros Corporation
Via
Business Wire
Omeros Corporation Reports Third Quarter 2022 Financial Results
November 09, 2022
From
Omeros Corporation
Via
Business Wire
Omeros Corporation Receives Decision from FDA on Formal Dispute Resolution Request for Narsoplimab
November 08, 2022
From
Omeros Corporation
Via
Business Wire
Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2022
November 04, 2022
From
Omeros Corporation
Via
Business Wire
Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting
November 03, 2022
From
Omeros Corporation
Via
Business Wire
Omeros Corporation Announces Royalty Monetization Transaction with DRI Healthcare Trust
October 03, 2022
From
Omeros Corporation
Via
Business Wire
Omeros Corporation Reports Narsoplimab Treatment Results in Critically Ill COVID-19 Patients in I-SPY COVID Trial
September 15, 2022
From
Omeros Corporation
Via
Business Wire
I-SPY COVID Trial Sponsored by Quantum Leap Healthcare Collaborative Reports Assessment of Narsoplimab for Treatment of Critically Ill Patients With COVID-19
September 15, 2022
From
Quantum Leap Healthcare Collaborative and Omeros Corporation
Via
Business Wire
Omeros Corporation Receives Interim Response from FDA on Formal Dispute Resolution Request for Narsoplimab
August 17, 2022
From
Omeros Corporation
Via
Business Wire
Omeros Corporation Reports Second Quarter 2022 Financial Results
August 09, 2022
From
Omeros Corporation
Via
Business Wire
Omeros Corporation to Announce Second Quarter Financial Results on August 9, 2022
August 04, 2022
From
Omeros Corporation
Via
Business Wire
FDA Grants Orphan Drug Designation to Omeros’ MASP-3 Inhibitor OMS906 for Treatment of Paroxysmal Nocturnal Hemoglobinuria
July 29, 2022
From
Omeros Corporation
Via
Business Wire
Omeros Announces Webcast Details for Annual Meeting of Shareholders
June 15, 2022
From
Omeros Corporation
Via
Business Wire
Small-Cap Psychedelic Play Vying for Future Leadership in Addiction Treatment (AXSM, AWKNF, BICX, OPNT, ALKS, PFE, AMPH, OMER)
June 06, 2022
Via
AB Newswire
Omeros Corporation Reports First Quarter 2022 Financial Results
May 10, 2022
From
Omeros Corporation
Via
Business Wire
Omeros Corporation to Announce First Quarter Financial Results on May 10, 2022
May 04, 2022
From
Omeros Corporation
Via
Business Wire
Omeros Announces Journal of Clinical Oncology Publication Detailing Pivotal Trial Results for Narsoplimab in HSCT-TMA
April 20, 2022
From
Omeros Corporation
Via
Business Wire
Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 1, 2022
February 24, 2022
From
Omeros Corporation
Via
Business Wire
Omeros Confirms Submission of Response to FDA Regarding the BLA for Narsoplimab in the Treatment of HSCT-TMA
January 19, 2022
From
Omeros Corporation
Via
Business Wire
Omeros Completes Sale of OMIDRIA® Franchise to Rayner Surgical
December 23, 2021
From
Omeros Corporation
Via
Business Wire
Omeros Corporation (NASDAQ:OMER) Investor Notice: Investigation over Potential Wrongdoing
December 14, 2021
San Diego, CA -- (SBWIRE) -- 12/14/2021 -- Certain directors of Omeros Corporation are under investigation over potential breaches of fiduciary duties.
Via
SBWire
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Omeros Corporation and Encourages Investors with Losses to Contact the Firm
December 05, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Product Safety
Omeros Announces Agreement to Sell OMIDRIA® Franchise to Rayner Surgical in a Transaction Valued in Excess of $1 Billion
December 02, 2021
From
Omeros Corporation
Via
Business Wire
Omeros Corporation Reports Third Quarter 2021 Financial Results
November 09, 2021
From
Omeros Corporation
Via
Business Wire
Omeros Announces Results From Nearly Three-Year Follow-up of Patients in Phase 2 IgA Nephropathy Trial
November 05, 2021
From
Omeros Corporation
Via
Business Wire
Omeros’ Narsoplimab Stabilized Kidney Function and Reduced Urinary Complement Proteins in a Patient with IgA Vasculitis
November 05, 2021
From
Omeros Corporation
Via
Business Wire
Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2021
November 04, 2021
From
Omeros Corporation
Via
Business Wire
NASDAQ:OMER Investor Notice: Investigation over Possible Securities Laws Violations by Omeros Corporation
October 22, 2021
San Diego, CA -- (SBWIRE) -- 10/22/2021 -- An investigation was announced concerning potential securities laws violations by Omeros Corporation in connection with certain financial statements.
Via
SBWire
Omeros Receives Complete Response Letter from FDA for Biologics License Application for Narsoplimab in the Treatment of HSCT-TMA
October 18, 2021
From
Omeros Corporation
Via
Business Wire
OMEROS ALERT: Bragar Eagel & Squire, P.C. is Investigating Omeros Corporation on Behalf of Omeros Stockholders and Encourages Investors to Contact the Firm
October 07, 2021
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.